Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Carboplatin + Gemcitabine in Recurrent Ovarian Cancer
NCT01133756Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2010
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib in ovarian cancer (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Dose Limiting Toxicity. Started Mar 2010; status: terminated.
02
Drugs
lenvatinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01133756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01133756.